Currently, Bic has become the most widely prescribed antiandrogenic medicine for treating prostate cancer (PCa)5, usually given as monotherapy (150 mg once daily) for treating early nonmetastatic PCa6. Here, MIR155HG is linked to posterior cortical atrophy.